FDA Approves Bristol Opdivo in Untreated Hodgkin Lymphoma

The FDA has approved a combination of nivolumab (Opdivo) plus the chemotherapy triplet of doxorubicin, vinblastine, and dacarbazine (AVD), for the treatment of patients 12 years and older with previously untreated, stage III or IV classical Hodgkin lymphoma, according to a news release from the agency.







https://www.cancernetwork.com/view/fda-approves-nivolumab-avd-in-untreated-hodgkin-lymphoma